One To Watch
AlzeCure Pharma
Company Overview
A Swedish CNS-focused biotech that has pivoted decisively to out-licensing, securing deals worth a combined headline value exceeding USD 3.2 billion in under a month by partnering its Alzheimer's and pain assets with Eli Lilly and QuantumCell ApS. AlzeCure Pharma AB develops small-molecule drugs across three platforms — NeuroRestore (cognitive/neurological), Alzstatin (Alzheimer's disease modification), and Painless (neuropathic pain) — and trades on Nasdaq First North Growth Market Stockholm under the ticker ALZCUR. The company retains corporate independence and continues to hold the Painless platform in-house while its neurology assets are now being advanced by well-resourced external partners.
Headquarters and Global Presence
AlzeCure is headquartered in Huddinge, Sweden, in the Karolinska/Novum life science cluster south of Stockholm. The company operates as a lean R&D organization with no disclosed manufacturing or commercial footprint beyond its Swedish base.
Founding and History
AlzeCure was founded in 2012 and listed on Nasdaq First North Growth Market Stockholm under the ticker ALZCUR. The company has operated with a small-cap profile typical of Nordic biotech, completing a fully-secured rights issue of approximately SEK 30.1 million to shore up its balance sheet before the transformative deal activity of mid-2026. Martin Jonsson was appointed chief executive with effect from January 9, 2024, and has overseen the company's shift toward an out-licensing model.
Therapy Areas and Focus
AlzeCure's primary disease focus is Alzheimer's disease, addressed through two mechanistically distinct approaches: synaptic enhancement via the NeuroRestore platform and amyloid modulation via Alzstatin. Its Painless platform targets neuropathic pain conditions, including the rare channelopathy erythromelalgia and broader indications such as osteoarthritis. The therapeutic logic is to address neurological and pain disorders where current standard of care is either absent or inadequate, creating defensible orphan and specialty positions.
Technology Platforms and Modalities
The NeuroRestore platform centers on small-molecule positive allosteric modulators of Trk receptors (Trk-PAMs), specifically enhancing NGF/TrkA and BDNF/TrkB neurotrophin signaling to improve neuronal communication and restore cognition. The Alzstatin platform employs gamma-secretase modulation, selectively reducing toxic amyloid-beta 42 while increasing the less harmful Abeta37/38 species — a differentiated angle in a field dominated by antibody-based amyloid clearance. The Painless platform uses TRPV1 antagonism (ACD440) and TrkA negative allosteric modulation (ACD137) to address pain at distinct molecular targets, giving the portfolio mechanistic breadth across the neurotrophin pathway.
Key Pipeline and Programs
ACD856 is AlzeCure's most advanced asset: a first-in-class Trk-PAM small molecule that completed Phase Ib on June 16, 2026, with a positive outcome — well-tolerated, no substance-related safety findings, and expected drug exposure confirmed in both blood and cerebrospinal fluid. Global rights to ACD856 and the broader NeuroRestore platform have been out-licensed to QuantumCell ApS, which will advance it into Phase II. ACD680 (Alzstatin) is a preclinical gamma-secretase modulator targeting the Abeta42/37/38 ratio; Eli Lilly acquired global rights to it on June 9, 2026, with a deal structured around a USD 10 million upfront payment, tiered mid-single-digit royalties, and milestones that could take total value above USD 1 billion. On the Painless platform, ACD440 — a TRPV1 antagonist — has completed Phase II with positive results and holds orphan drug designation from both FDA and EMA for erythromelalgia, with a registrational study in preparation; ACD137, a TrkA-NAM targeting osteoarthritis and neuropathic pain, is advancing toward clinical entry.
Recent Developments
The defining events of mid-2026 were two out-licensing deals executed within weeks of each other. On June 9, 2026, AlzeCure announced that Eli Lilly had taken global rights to the preclinical Alzstatin asset ACD680 for USD 10 million upfront plus milestones potentially exceeding USD 1 billion. On July 1, 2026, AlzeCure announced the out-licensing of the entire NeuroRestore platform — including the Phase I-complete ACD856 — to QuantumCell ApS for USD 12 million upfront (of which USD 5 million is a direct equity investment in AlzeCure at a 30% premium to the 10-day average share price of SEK 3.78) plus milestones, with total deal value exceeding USD 2.2 billion excluding royalties. On February 24, 2026, ACD440 received EU orphan drug designation for erythromelalgia, complementing its existing FDA orphan status.
Key Personnel
Martin Jonsson serves as Chief Executive Officer, appointed with effect from January 9, 2024. He has overseen AlzeCure's strategic transition to an out-licensing model, concluding deals with Eli Lilly and QuantumCell ApS totaling more than USD 3.2 billion in headline deal value within a single month.
Strategic Partnerships
The QuantumCell ApS agreement (July 1, 2026) grants the Danish VC-backed startup — backed by Lundbeckfonden, Novo Holdings, Forbion Ventures, and First Spark Ventures — global rights to the NeuroRestore platform including ACD856, structured as USD 12 million upfront plus milestone-heavy biobucks exceeding USD 2.2 billion and tiered royalties. The Eli Lilly collaboration (June 9, 2026) covering ACD680 (Alzstatin) provides USD 10 million upfront with milestones potentially exceeding USD 1 billion and tiered mid-single-digit royalties, bringing a major pharma partner into the amyloid-modulation program at preclinical stage.
FAQ Section
With cash and cash equivalents of approximately SEK 33 million at the end of Q1 2026 and a recent rights issue of SEK 30.1 million to sustain operations, AlzeCure lacked the balance sheet to self-fund Phase II and beyond in Alzheimer's. Out-licensing to Eli Lilly (ACD680) and QuantumCell (ACD856) converts milestone-contingent value into near-term cash and transfers the capital-intensive development burden to partners, while AlzeCure retains royalty economics and keeps the Painless platform in-house.
Neurotrophin signaling through TrkA and TrkB receptors — activated by NGF and BDNF respectively — is essential for synaptic plasticity and neuronal survival, both of which are impaired in Alzheimer's. Rather than blocking the receptor or delivering the growth factor directly (approaches that have historically failed due to poor CNS penetration or systemic side effects), ACD856 acts as a positive allosteric modulator, sensitizing the receptor to its endogenous ligand. Phase Ib data confirmed meaningful CNS exposure in cerebrospinal fluid, validating the pharmacokinetic premise for a brain-penetrant small molecule in this target class.
Approved amyloid therapies such as lecanemab and donanemab use antibodies to clear aggregated amyloid-beta from the brain, a mechanism associated with amyloid-related imaging abnormalities (ARIA). ACD680 takes a different route: as a gamma-secretase modulator it shifts production away from the toxic Abeta42 species toward the less harmful Abeta37 and Abeta38 peptides, addressing the problem upstream at the level of amyloid generation rather than clearance. The preclinical-stage asset's potential is validated by Eli Lilly's willingness to license it for up to USD 1 billion in milestones alongside their own approved amyloid antibody.
ACD440 is a TRPV1 antagonist that has completed Phase II with positive results and holds orphan drug designation from both the FDA and EMA for erythromelalgia — a rare, severely debilitating condition of pathological burning pain for which there is no approved pharmacological treatment. The dual orphan status provides regulatory incentives (market exclusivity, fee waivers) and a clear, well-characterized patient population for a registrational study that AlzeCure is preparing. The combination of positive Phase II data and regulatory designation makes ACD440 a credible out-licensing or partnering target in its own right.
All three platforms — NeuroRestore, Alzstatin, Painless — sit within the neurotrophin and neurodegeneration space, giving the portfolio genuine mechanistic coherence. NeuroRestore and the Painless TrkA-NAM program (ACD137) both engage the Trk receptor family, albeit in opposite directions: ACD856 potentiates TrkA/TrkB signaling to restore cognition, while ACD137 inhibits TrkA to block pain transmission. This shared pathway expertise is a strategic asset, and the breadth across CNS and pain creates optionality if one platform fails to advance.
AlzeCure is now primarily a royalty- and milestone-bearing licensor for its two most advanced CNS programs. Phase II initiation for ACD856 will be driven by QuantumCell; clinical development of ACD680 is Eli Lilly's responsibility. Internally, AlzeCure retains ACD440, which is the most clinically mature asset it still controls, with a registrational study in erythromelalgia as the next step. ACD137 (TrkA-NAM) is approaching its own clinical entry, which would be the next internal development catalyst to watch.
Key catalysts and watchpoints include:
- Registrational study design and initiation for ACD440 in erythromelalgia — the most direct near-term internal milestone.
- QuantumCell's Phase II initiation for ACD856: a newly-formed, stealthy counterparty with no commercial track record, backed by Novo Holdings and Lundbeckfonden, carries execution risk despite credible investors.
- Milestone achievement under both deals: the USD 2.2 billion (NeuroRestore/QuantumCell) and USD 1 billion (ACD680/Lilly) headlines are contingent biobucks — actual near-term cash from the QuantumCell deal is approximately USD 7 million (the USD 12 million upfront less the USD 5 million reinvested as equity in AlzeCure).
- Balance sheet sustainability: with pre-deal cash around SEK 33 million and ongoing operating losses, AlzeCure remains dependent on deal inflows and milestone receipts to fund operations.
- ACD137 (TrkA-NAM) clinical entry in osteoarthritis/neuropathic pain — a potential additional licensing event.
Latest AlzeCure Pharma News
Today's issue
| Headless Content Management with Blaze